Patient Safety Organizations: Voluntary Relinquishment From Diagnostic Quality Assurance, 36937 [2018-16327]
Download as PDF
<![CDATA[
Federal Register / Vol. 83, No. 147 / Tuesday, July 31, 2018 / Notices
thresholds for certain data items to
reduce reporting burden. The comment
period expired June 29, 2018.
Detailed Discussion of Public
Comments
The Federal Reserve received one
comment from a banking association.
The commenter noted several
inconsistencies on the FR Y–9C report
form and one inconsistency on the
instructions when compared to the Call
Report pertaining to Schedule HC–Q
Memoranda items 4.b and 4.d, column
A and Schedule HC–S Column G
instructions and requested clarification
on the proper reporting. The draft report
form was inadvertently updated to
reflect the removal of items 4.b and 4.d
and a line item reference on the
instructions for Schedule HC–S Column
G was also inadvertently struck through.
The Board has revised these items so
that both the report form and
instructions align with the Call Report.
Additionally, the commenter noted an
inconsistency between the caption on
the report form and the caption on the
instructions pertaining to Equity
investments without readily
determinable fair values on Schedule
HC–F line item 4 on the FR Y–9C report.
The Board has updated the instructions
so that the report form and instructions
align.
The revisions will be implemented as
proposed, with the modifications
described above, effective for the June
30, 2018, report date.
Board of Governors of the Federal Reserve
System, July 25, 2018.
Michele Taylor Fennell,
Assistant Secretary of the Board.
[FR Doc. 2018–16265 Filed 7–30–18; 8:45 am]
BILLING CODE 6210–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Healthcare Research and
Quality
Patient Safety Organizations:
Voluntary Relinquishment From
Diagnostic Quality Assurance
Agency for Healthcare Research
and Quality (AHRQ), Department of
Health and Human Services (HHS).
ACTION: Notice of delisting.
daltland on DSKBBV9HB2PROD with NOTICES
AGENCY:
The Patient Safety Rule
authorizes AHRQ, on behalf of the
Secretary of HHS, to list as a PSO an
entity that attests that it meets the
statutory and regulatory requirements
for listing. A PSO can be ‘‘delisted’’ by
the Secretary if it is found to no longer
SUMMARY:
VerDate Sep<11>2014
18:30 Jul 30, 2018
Jkt 244001
meet the requirements of the Patient
Safety Act and Patient Safety Rule,
when a PSO chooses to voluntarily
relinquish its status as a PSO for any
reason, or when a PSO’s listing expires.
AHRQ has accepted a notification of
voluntary relinquishment from
Diagnostic Quality Assurance of its
status as a PSO, and has delisted the
PSO accordingly. Diagnostic Quality
Assurance, PSO number P0170,
submitted this request for voluntary
relinquishment after receiving a Notice
of Preliminary Finding of Deficiency.
DATES: The directories for both listed
and delisted PSOs are ongoing and
reviewed weekly by AHRQ. The
delisting was effective at 12:00 Midnight
ET (2400) on July 1, 2018.
ADDRESSES: Both directories can be
accessed electronically at the following
HHS website: https://www.pso.ahrq.gov/
listed.
FOR FURTHER INFORMATION CONTACT:
Eileen Hogan, Center for Quality
Improvement and Patient Safety, AHRQ,
5600 Fishers Lane, Room 06N94B,
Rockville, MD 20857; Telephone (toll
free): (866) 403–3697; Telephone (local):
(301) 427–1111; TTY (toll free): (866)
438–7231; TTY (local): (301) 427–1130;
Email: pso@ahrq.hhs.gov.
SUPPLEMENTARY INFORMATION:
Background
The Patient Safety and Quality
Improvement Act of 2005, 42 U.S.C.
299b–21 to b–26, (Patient Safety Act)
and the related Patient Safety and
Quality Improvement Final Rule, 42
CFR part 3 (Patient Safety Rule),
published in the Federal Register on
November 21, 2008, 73 FR 70732–
70814, establish a framework by which
hospitals, doctors, and other health care
providers may voluntarily report
information to Patient Safety
Organizations (PSOs), on a privileged
and confidential basis, for the
aggregation and analysis of patient
safety events.
The Patient Safety Act authorizes the
listing of PSOs, which are entities or
component organizations whose
mission and primary activity are to
conduct activities to improve patient
safety and the quality of health care
delivery.
HHS issued the Patient Safety Rule to
implement the Patient Safety Act.
AHRQ administers the provisions of the
Patient Safety Act and Patient Safety
Rule relating to the listing and operation
of PSOs. The Patient Safety Rule
authorizes AHRQ to list as a PSO an
entity that attests that it meets the
statutory and regulatory requirements
for listing. A PSO can be ‘‘delisted’’ if
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
36937
it is found to no longer meet the
requirements of the Patient Safety Act
and Patient Safety Rule, when a PSO
chooses to voluntarily relinquish its
status as a PSO for any reason, or when
a PSO’s listing expires. Section 3.108(d)
of the Patient Safety Rule requires
AHRQ to provide public notice when it
removes an organization from the list of
federally approved PSOs.
AHRQ has accepted a notification
from Diagnostic Quality Assurance, a
component entity of Quality Star, LLC,
to voluntarily relinquish its status as a
PSO. Accordingly, Diagnostic Quality
Assurance was delisted effective at
12:00 Midnight ET (2400) on July 1,
2018. AHRQ notes that that Diagnostic
Quality Assurance submitted this
request for voluntary relinquishment
following receipt of the Notice of
Preliminary Finding of Deficiency sent
on April 10, 2018.
More information on PSOs can be
obtained through AHRQ’s PSO website
at https://www.pso.ahrq.gov.
Francis D. Chesley, Jr.,
Acting Deputy Director.
[FR Doc. 2018–16327 Filed 7–30–18; 8:45 am]
BILLING CODE 4160–90–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2017–N–0007]
Biosimilar User Fee Rates for Fiscal
Year 2019
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing the
rates for biosimilar user fees for fiscal
year (FY) 2019. The Federal Food, Drug,
and Cosmetic Act (FD&C Act), as
amended by the Biosimilar User Fee
Amendments of 2017 (BsUFA II),
authorizes FDA to assess and collect
user fees for certain activities in
connection with biosimilar biological
product development; review of certain
applications for approval of biosimilar
biological products; and each biosimilar
biological product approved in a
biosimilar biological product
application.
BsUFA II directs FDA to establish,
before the beginning of each fiscal year,
the amount of initial and annual
biosimilar biological product
development (BPD) fees, the
reactivation fee, and the biosimilar
biological product application and
SUMMARY:
E:\FR\FM\31JYN1.SGM
31JYN1
]]>Agencies
[Federal Register Volume 83, Number 147 (Tuesday, July 31, 2018)]
[Notices]
[Page 36937]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-16327]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Agency for Healthcare Research and Quality
Patient Safety Organizations: Voluntary Relinquishment From
Diagnostic Quality Assurance
AGENCY: Agency for Healthcare Research and Quality (AHRQ), Department
of Health and Human Services (HHS).
ACTION: Notice of delisting.
-----------------------------------------------------------------------
SUMMARY: The Patient Safety Rule authorizes AHRQ, on behalf of the
Secretary of HHS, to list as a PSO an entity that attests that it meets
the statutory and regulatory requirements for listing. A PSO can be
``delisted'' by the Secretary if it is found to no longer meet the
requirements of the Patient Safety Act and Patient Safety Rule, when a
PSO chooses to voluntarily relinquish its status as a PSO for any
reason, or when a PSO's listing expires. AHRQ has accepted a
notification of voluntary relinquishment from Diagnostic Quality
Assurance of its status as a PSO, and has delisted the PSO accordingly.
Diagnostic Quality Assurance, PSO number P0170, submitted this request
for voluntary relinquishment after receiving a Notice of Preliminary
Finding of Deficiency.
DATES: The directories for both listed and delisted PSOs are ongoing
and reviewed weekly by AHRQ. The delisting was effective at 12:00
Midnight ET (2400) on July 1, 2018.
ADDRESSES: Both directories can be accessed electronically at the
following HHS website: https://www.pso.ahrq.gov/listed.
FOR FURTHER INFORMATION CONTACT: Eileen Hogan, Center for Quality
Improvement and Patient Safety, AHRQ, 5600 Fishers Lane, Room 06N94B,
Rockville, MD 20857; Telephone (toll free): (866) 403-3697; Telephone
(local): (301) 427-1111; TTY (toll free): (866) 438-7231; TTY (local):
(301) 427-1130; Email: [email protected].
SUPPLEMENTARY INFORMATION:
Background
The Patient Safety and Quality Improvement Act of 2005, 42 U.S.C.
299b-21 to b-26, (Patient Safety Act) and the related Patient Safety
and Quality Improvement Final Rule, 42 CFR part 3 (Patient Safety
Rule), published in the Federal Register on November 21, 2008, 73 FR
70732-70814, establish a framework by which hospitals, doctors, and
other health care providers may voluntarily report information to
Patient Safety Organizations (PSOs), on a privileged and confidential
basis, for the aggregation and analysis of patient safety events.
The Patient Safety Act authorizes the listing of PSOs, which are
entities or component organizations whose mission and primary activity
are to conduct activities to improve patient safety and the quality of
health care delivery.
HHS issued the Patient Safety Rule to implement the Patient Safety
Act. AHRQ administers the provisions of the Patient Safety Act and
Patient Safety Rule relating to the listing and operation of PSOs. The
Patient Safety Rule authorizes AHRQ to list as a PSO an entity that
attests that it meets the statutory and regulatory requirements for
listing. A PSO can be ``delisted'' if it is found to no longer meet the
requirements of the Patient Safety Act and Patient Safety Rule, when a
PSO chooses to voluntarily relinquish its status as a PSO for any
reason, or when a PSO's listing expires. Section 3.108(d) of the
Patient Safety Rule requires AHRQ to provide public notice when it
removes an organization from the list of federally approved PSOs.
AHRQ has accepted a notification from Diagnostic Quality Assurance,
a component entity of Quality Star, LLC, to voluntarily relinquish its
status as a PSO. Accordingly, Diagnostic Quality Assurance was delisted
effective at 12:00 Midnight ET (2400) on July 1, 2018. AHRQ notes that
that Diagnostic Quality Assurance submitted this request for voluntary
relinquishment following receipt of the Notice of Preliminary Finding
of Deficiency sent on April 10, 2018.
More information on PSOs can be obtained through AHRQ's PSO website
at https://www.pso.ahrq.gov.
Francis D. Chesley, Jr.,
Acting Deputy Director.
[FR Doc. 2018-16327 Filed 7-30-18; 8:45 am]
BILLING CODE 4160-90-P
